Skip to main content

Advertisement

SpringerLink
Log in
Menu
Find a journal Publish with us Track your research
Search
Cart
  1. Home
  2. Current Treatment Options in Oncology
  3. Article

Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer

  • Genitourinary Cancer
  • Published: 22 August 2007
  • Volume 8, pages 211–226, (2007)
  • Cite this article
Download PDF
Current Treatment Options in Oncology Aims and scope Submit manuscript
Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer
Download PDF
  • Naomi B. Haas1 &
  • Robert G. Uzzo MD2 

  • 167 Accesses

  • 10 Citations

  • Explore all metrics

Opinion statements

Renal cell carcinoma (RCC) is a heterogeneous disease as reflected in its presentation and clinical course, pathological subtypes, nuclear grades and molecular biology. Emerging data indicate that renal tumors express a variety of molecular tumor markers and unique patterns of gene expression. Clinically the disease behaves quite heterogeneously, with courses ranging from indolent to highly aggressive. Surgical monotherapy or as part of a multimodal approach remains the standard of care for most cases of RCC. Radical or partial nephrectomy is associated with a 5-year cancer specific survival (CSS) of 85–97% for pT1 tumors. Unfortunately, 20% of patients have either locally advanced or node positive (N+) RCC while another 22% have metastatic RCC (mRCC) at presentation. Unlike the outcomes in early localized disease, survival rates for N+ patients are poor and patients with mRCC are rarely cured despite aggressive multimodal therapy. Classic cytotoxic chemotherapy has repeatedly been shown to have little effect and only 5–20% of patients with mRCC respond to immunologic agents such as interferon and/or interleukin. Cytoreductive nephrectomy with systemic immunotherapy is associated with few cures with median survivals of 12–24 months. Recent advances in our understanding of the molecular origins and pathways of RCC have led to the development of more effective targeted therapies. Here we review the molecular pathways that define the pertinent therapeutic targets in RCC and the clinical data for these new and promising agents.

Article PDF

Download to read the full article text

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: ●Of importance ●● Of major importance

  1. Jemal A, Murray T, Ward E, et al.: Cancer statistics. CA Cancer J Clin 2005, 55:10–30

    PubMed  Google Scholar 

  2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477–2490

    Article  CAS  PubMed  Google Scholar 

  3. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG: The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006, 175:425–431

    Article  PubMed  Google Scholar 

  4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2005, 25(1):CD001425

    Google Scholar 

  5. Frank I, Blute ML, Leibovich BC, et al.: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889–1892

    Article  PubMed  Google Scholar 

  6. Moinzadeh A, Gill IS, Finelli A, Kaouk J, Desai M: Laparoscopic partial nephrectomy: 3-year followup. J Urol 2006, 175:459–462

    Article  PubMed  Google Scholar 

  7. Gill IS, Remer EM, Hasan WA, et al.: Renal cryoablation: outcome at 3 years. J Urol 2005, 173:1903–1907

    Article  PubMed  Google Scholar 

  8. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20(2):303–321

    CAS  PubMed  Google Scholar 

  9. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001, 345:1655–1659

    Article  CAS  PubMed  Google Scholar 

  10. Enquist E, Zambrano N, Zbar B, et al: Molecular genetics of renal cell carcinoma. In Bukowski RM, Novick AC (eds). Renal Cell Carcinoma: Molecular biology, Immunology, and Clinical Management. Totowa, N.J.: Humana Press Inc, 2000;pp 79–93

    Google Scholar 

  11. Knudson AG Jr.: Genetics of human cancer. Annu Rev Genet 1986, 20:231–251

    Article  PubMed  Google Scholar 

  12. Uzzo RG, Novick AC: von Hippel Lindau syndrome: clinical and molecular considerations for the urologist. AUA Update Ser 1999, 18:137–144

    Google Scholar 

  13. Lubensky IA, Schmidt L, Zhuang Z, et al.: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155:517–526

    CAS  PubMed  Google Scholar 

  14. Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V: The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003, 30:423–436

    Article  PubMed  Google Scholar 

  15. Baylin SB, Herman JG, Graff JR, et al.: Alterations in DNA methylation: a fundamental aspects of neoplasia. Adv Cancer Res 1998, 72:141–196

    Article  CAS  PubMed  Google Scholar 

  16. Gnarra JR, Lerman MI, Zbar B, et al.: Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995, 22:3–8

    CAS  PubMed  Google Scholar 

  17. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995, 273:564–570

    Article  CAS  PubMed  Google Scholar 

  18. Foster K, Prowse A, van den Berg A, et al.: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3:2169–2173

    Article  CAS  PubMed  Google Scholar 

  19. Hatano N, Nishikawa NS, McElgunn C, et al.: A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library. Mol Carcinog 2001, 31:161–170

    Article  CAS  PubMed  Google Scholar 

  20. Schmidt L, Duh FM, Chen F, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68–73

    Article  CAS  PubMed  Google Scholar 

  21. Speicher MR, Schoell B, du Manoir S, et al.: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994, 145:356–364

    CAS  PubMed  Google Scholar 

  22. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005, 104(11):2323–2333

    Article  CAS  PubMed  Google Scholar 

  23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327–337

    CAS  PubMed  Google Scholar 

  24. O’Farrel AM, et al.: SU 11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in␣vitro and in␣vivo. Blood 2003, 101:3597

    Article  CAS  Google Scholar 

  25. Fiedler W, et al.: A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood 2004, 5:1846

    Google Scholar 

  26. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516–2524

    Article  CAS  PubMed  Google Scholar 

  27. Motzer RJ, et al.: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: results of a phase II study. Proc Am Soc Clin Oncol 2004, Abs#4500

  28. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368(9544):1329–1338

    Article  CAS  PubMed  Google Scholar 

  29. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Kim ST, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115–124

    Article  CAS  PubMed  Google Scholar 

  30. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Bollag G, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Trail PA: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099–7109

    Article  CAS  PubMed  Google Scholar 

  31. Escudier B, Eisen T. Stadler W, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125–134

    Article  CAS  PubMed  Google Scholar 

  32. Szczylik C, Demkow T, Staehler M, et al.: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S):5025

  33. Amato RJ, Harris P, Dalton M, et al.: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S):5026

  34. Rini B, Rixe O, Bukowski R, et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement):4509

  35. Hurwitz H, Dowlati A, Savage S, et al.: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement):3012

  36. Albert DH, Tapang P, Magoc TJ, et al.: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4):995–1006

    Article  CAS  PubMed  Google Scholar 

  37. Van Cruijsen H, Voest EE, Van Herpen CM, et al.: Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24(18S):3017

  38. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL: FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 1993, 268:22825–22829

    CAS  PubMed  Google Scholar 

  39. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19(56):6680–6686

    Article  CAS  PubMed  Google Scholar 

  40. Brown EJ, Albers MW, Shin TB, Ocjlawa K, Keith CT, Lane WS, Schreiber SLA: Mammalian protein targeted by G1-arresting rapamycin receptor complex. Nature 1994, 369:756–758

    Article  CAS  PubMed  Google Scholar 

  41. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66(11):5549–5554

    Article  PubMed  Google Scholar 

  42. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271–2281

    Article  CAS  PubMed  Google Scholar 

  43. Figlin RA, Seligson D, Wu H, et al.: Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S) Part I of II (June 1 Supplement):4539

  44. Amato RJ, Misellati A, Khan M, Chiang S: A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24(18S):4530

  45. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5):427–434.

    Article  CAS  PubMed  Google Scholar 

  46. Rini B, Halabi S, Taylor J, et al.: Cancer and leukemia group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10(8):2584–2586.

    Article  CAS  PubMed  Google Scholar 

  47. Escudier B, Koralewski P, Pluzanska A, et al.: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I, 2007, 25(18S):3

  48. Veronese ML, Mosenkis A, Flaherty KT, et al.: Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 2006, 24(9):1363–1369

    Article  CAS  PubMed  Google Scholar 

  49. Govindarajan R, Adusumilli J, Baxter DL, et al.: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol 2006, 24(28):e48

    Article  PubMed  Google Scholar 

  50. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23(13):2900–2922

    Article  CAS  PubMed  Google Scholar 

  51. Robert C, Soria JC, Spatz A, et al.: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6(7):491–500

    Article  CAS  PubMed  Google Scholar 

  52. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984, 101(6):798–799

    CAS  PubMed  Google Scholar 

  53. Robert C, Faivre S, Raymond E, et al.: Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005, 143(4):313–314

    PubMed  Google Scholar 

  54. Routhouska S, Gilliam AC, Mirmirani P: Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006, 142(11):1477–1479

    Google Scholar 

  55. Desai J, Yassa L, Marqusee E, et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006, 145(9):660–664

    PubMed  Google Scholar 

  56. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542–2550

    Article  CAS  PubMed  Google Scholar 

  57. Investigator Safety Report for CCI-779, Investigator’s Brochure April, 2005

  58. Duran I, Sin LL, Oza Am, et al.: Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006, 42(12):1875–1880

    Article  CAS  PubMed  Google Scholar 

  59. Galanis E, Buckner JC, Maurer MJ, et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294–5304

    Article  CAS  PubMed  Google Scholar 

  60. Chang SM, Wen P, Cloughesy T, et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357–361

    Article  CAS  PubMed  Google Scholar 

  61. Huffman TA, Mothe-Satney I, Lawrence JC Jr.: Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci USA 2002, 99(2):1047–1052

    Article  CAS  PubMed  Google Scholar 

  62. Kunkle DA, Haas NB, Uzzo RG: Adjuvant strategies for high risk renal cell carcinoma patients. Curr Urol Rep 2007, 8(1):19–30

    Article  PubMed  Google Scholar 

  63. Jocham D, Richter A, Hoffman L, et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet 2004, 363:594–599

    Article  CAS  PubMed  Google Scholar 

  64. Uzzo RG, Novick AC: The role of nephrectomy and metastasectomy in advanced renal cell carcinoma. In: Bukowski RM, Novick AC (eds) Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management. Totowa, NJ: The Humana Press, (2000); pp 215–228

    Google Scholar 

  65. Mickisch GA, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358(9286):966–970

    Article  CAS  PubMed  Google Scholar 

  66. Halbert RJ, Figlin RA, Atkin MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois R: Treatments for patients with metastatic renal cell cancer: a rand appropriateness panel. Cancer 2006, 107(10):2375–2383

    Article  CAS  PubMed  Google Scholar 

  67. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91(3):173–180

    Article  CAS  PubMed  Google Scholar 

  68. D’Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case–control study. Ann Surg Oncol 2007, 14:759–765

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Naomi B. Haas

  2. The Department of Urologic Oncology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Robert G. Uzzo MD

Authors
  1. Naomi B. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Uzzo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert G. Uzzo MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haas, N.B., Uzzo, R.G. Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer. Curr. Treat. Options in Oncol. 8, 211–226 (2007). https://doi.org/10.1007/s11864-007-0031-3

Download citation

  • Published: 22 August 2007

  • Issue Date: June 2007

  • DOI: https://doi.org/10.1007/s11864-007-0031-3

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our imprints

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Cancel contracts here

18.207.133.13

Not affiliated

Springer Nature

© 2024 Springer Nature